Literature DB >> 22094259

IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

Damien Reynaud1, Eric Pietras, Keegan Barry-Holson, Alain Mir, Mikhail Binnewies, Marion Jeanne, Olga Sala-Torra, Jerald P Radich, Emmanuelle Passegué.   

Abstract

Using a mouse model recapitulating the main features of human chronic myelogenous leukemia (CML), we uncover the hierarchy of leukemic stem and progenitor cells contributing to disease pathogenesis. We refine the characterization of CML leukemic stem cells (LSCs) to the most immature long-term hematopoietic stem cells (LT-HSCs) and identify some important molecular deregulations underlying their aberrant behavior. We find that CML multipotent progenitors (MPPs) exhibit an aberrant B-lymphoid potential but are redirected toward the myeloid lineage by the action of the proinflammatory cytokine IL-6. We show that BCR/ABL activity controls Il-6 expression thereby establishing a paracrine feedback loop that sustains CML development. These results describe how proinflammatory tumor environment affects leukemic progenitor cell fate and contributes to CML pathogenesis. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094259      PMCID: PMC3220886          DOI: 10.1016/j.ccr.2011.10.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  34 in total

1.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

Authors:  X Jiang; A Lopez; T Holyoake; A Eaves; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 2.  Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies.

Authors:  Matthew R Warr; Eric M Pietras; Emmanuelle Passegué
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011-03-15

3.  Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.

Authors:  S Li; S Gillessen; M H Tomasson; G Dranoff; D G Gilliland; R A Van Etten
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

4.  Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.

Authors:  M Porosnicu; R Nimmanapalli; D Nguyen; E Worthington; C Perkins; K N Bhalla
Journal:  Leukemia       Date:  2001-05       Impact factor: 11.528

5.  Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis.

Authors:  M Anand; S K Chodda; P M Parikh; J S Nadkarni
Journal:  Hematol Oncol       Date:  1998-12       Impact factor: 5.271

6.  Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.

Authors:  X Zhang; R Ren
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

7.  Impaired immune and acute-phase responses in interleukin-6-deficient mice.

Authors:  M Kopf; H Baumann; G Freer; M Freudenberg; M Lamers; T Kishimoto; R Zinkernagel; H Bluethmann; G Köhler
Journal:  Nature       Date:  1994-03-24       Impact factor: 49.962

8.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Authors:  Cihangir Duy; Christian Hurtz; Seyedmehdi Shojaee; Leandro Cerchietti; Huimin Geng; Srividya Swaminathan; Lars Klemm; Soo-mi Kweon; Rahul Nahar; Melanie Braig; Eugene Park; Yong-mi Kim; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; J Jessica Yu; Nora Heisterkamp; Thomas G Graeber; Hong Wu; B Hilda Ye; Ari Melnick; Markus Müschen
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

9.  A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

Authors:  Apostolos Klinakis; Camille Lobry; Omar Abdel-Wahab; Philmo Oh; Hiroshi Haeno; Silvia Buonamici; Inge van De Walle; Severine Cathelin; Thomas Trimarchi; Elisa Araldi; Cynthia Liu; Sherif Ibrahim; Miroslav Beran; Jiri Zavadil; Argiris Efstratiadis; Tom Taghon; Franziska Michor; Ross L Levine; Iannis Aifantis
Journal:  Nature       Date:  2011-05-12       Impact factor: 49.962

Review 10.  Cell cycle regulation in hematopoietic stem cells.

Authors:  Eric M Pietras; Matthew R Warr; Emmanuelle Passegué
Journal:  J Cell Biol       Date:  2011-11-28       Impact factor: 10.539

View more
  160 in total

1.  Ischemic stroke activates hematopoietic bone marrow stem cells.

Authors:  Gabriel Courties; Fanny Herisson; Hendrik B Sager; Timo Heidt; Yuxiang Ye; Ying Wei; Yuan Sun; Nicolas Severe; Partha Dutta; Jennifer Scharff; David T Scadden; Ralph Weissleder; Filip K Swirski; Michael A Moskowitz; Matthias Nahrendorf
Journal:  Circ Res       Date:  2014-10-31       Impact factor: 17.367

2.  Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling.

Authors:  Heather A Himburg; Martina Roos; Tiancheng Fang; Yurun Zhang; Christina M Termini; Lauren Schlussel; Mindy Kim; Amara Pang; Jenny Kan; Liman Zhao; Hyung Suh; Joshua P Sasine; Gopal Sapparapu; Peter M Bowers; Gary Schiller; John P Chute
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 3.  Regulation of stress-induced hematopoiesis.

Authors:  Jimmy L Zhao; David Baltimore
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

4.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

5.  Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.

Authors:  Daniel A Pollyea; Chelsea Harris; Jennifer L Rabe; Brenna R Hedin; Lesly De Arras; Sigrid Katz; Emily Wheeler; Rafael Bejar; Matthew J Walter; Craig T Jordan; Eric M Pietras; Scott Alper
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

6.  PI3K Is a Linker Between L-selectin and PSGL-1 Signaling to IL-18 Transcriptional Activation at the Promoter Level.

Authors:  Jixian Luo
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 7.  Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases.

Authors:  Yukino Chiba; Izuru Mizoguchi; Hideaki Hasegawa; Mio Ohashi; Naoko Orii; Taro Nagai; Miyaka Sugahara; Yasunori Miyamoto; Mingli Xu; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Cell Mol Life Sci       Date:  2017-12-07       Impact factor: 9.261

Review 8.  Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.

Authors:  Aline Renneville; Mrinal M Patnaik; Onyee Chan; Eric Padron; Eric Solary
Journal:  Leukemia       Date:  2021-06-26       Impact factor: 11.528

9.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

10.  p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion.

Authors:  Bangxing Hong; Haiyan Li; Mingjun Zhang; Jingda Xu; Yong Lu; Yuhuan Zheng; Jianfei Qian; Jeffrey T Chang; Jing Yang; Qing Yi
Journal:  Int J Cancer       Date:  2014-05-16       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.